[{"id":"0a7234f9-0a21-4819-ace5-9082ae1d4a9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02859441","created_at":"2021-01-18T14:02:14.116Z","updated_at":"2024-07-02T16:36:21.931Z","phase":"Phase 1/2","brief_title":"A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab","source_id_and_acronym":"NCT02859441","lead_sponsor":"National Eye Institute (NEI)","biomarkers":" VHL","pipe":" | ","alterations":" VHL mutation","tags":["VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fovista (pegpleranib) • Lucentis (ranibizumab)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 01/23/2017","start_date":" 01/23/2017","primary_txt":" Primary completion: 07/09/2019","primary_completion_date":" 07/09/2019","study_txt":" Completion: 07/09/2019","study_completion_date":" 07/09/2019","last_update_posted":"2021-11-01"}]